Fusion proteins comprising DP-178 and other viral fusion inhibitor peptides useful for treating aids
US7122190B2 · kind B2 · utility
5Cited by
25References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 9, 2002 |
| Grant date | Oct 17, 2006 |
| Priority date | — |
| Expiry date | Oct 24, 2022 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S530/826
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID:1) peptide corresponding to amino acids 638 to 673 of the HIV-1LAI gp41 protein, and fragments, analogs and homologs of DP178. The invention further relates to the uses of such peptides as inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.